keyword
MENU ▼
Read by QxMD icon Read
search

Sulbactam acinetobacter

keyword
https://www.readbyqxmd.com/read/29609277/-analysis-of-distribution-and-drug-resistance-of-pathogens-of-burn-patients-during-9-years
#1
Y Dou, Q Zhang
Objective: To investigate distribution and drug resistance of pathogens of burn patients. Methods: A total of 3 357 strains were cultured and isolated from 25 286 specimens of wounds excretion, deep venous catheters, venous blood, stool, mid-stream urine, sputum, puncture fluid, and throat swab of 11 510 burn patients hospitalized in our burn wards from January 2007 to December 2015. After being identified by API bacteria identification panels and automatically bacteria identification equipment, drug-resistances of Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae to 28 common antibiotics were tested by drug sensitivity test with K-B paper disk diffusion method...
March 20, 2018: Zhonghua Shao Shang za Zhi, Zhonghua Shaoshang Zazhi, Chinese Journal of Burns
https://www.readbyqxmd.com/read/29593912/antimicrobial-susceptibility-among-colistin-sulbactam-and-fosfomycin-and-a-synergism-study-of-colistin-in-combination-with-sulbactam-or-fosfomycin-against-clinical-isolates-of-carbapenem-resistant-acinetobacter-baumannii
#2
Sombat Leelasupasri, Wichai Santimaleeworagun, Tossawan Jitwasinkul
This in vitro study aimed to determine the activity of colistin plus sulbactam and colistin plus fosfomycin against carbapenem-resistant A. baumannii (CRAB). Fifteen clinical isolates were obtained from patients admitted to Phyathai II International Hospital, Bangkok, Thailand, from August 2014 to April 2015. The antimicrobial susceptibilities of colistin, sulbactam, and fosfomycin were evaluated using the E-test or broth microdilution and the synergistic activity of the antibacterial combinations (colistin plus sulbactam or fosfomycin) was determined using the chequerboard method...
2018: Journal of Pathogens
https://www.readbyqxmd.com/read/29548877/antibiotic-consumption-versus-the-prevalence-of-multidrug-resistant-acinetobacter-baumannii-and-clostridium-difficile-infections-at-an-icu-from-2014-2015
#3
Grzegorz Ziółkowski, Iwona Pawłowska, Lech Krawczyk, Jadwiga Wojkowska-Mach
BACKGROUND: Acinetobacter baumannii strains are currently the most commonly isolated non-fermenting rods at Polish intensive care units (ICUs), and they are the dominant aetiological agents of pneumonia. This study aimed to evaluate the prevalence of A. baumannii isolated from patients who were hospitalised at Sosnowiec Hospital's ICU. We also investigated the drug sensitivity of A. baumannii in relation to antibiotic consumption expressed as the defined daily dose (DDD) and Clostridium difficile infection (CDI)...
March 13, 2018: Journal of Infection and Public Health
https://www.readbyqxmd.com/read/29531445/colistin-versus-colistin-combined-with-ampicillin-sulbactam-for-multiresistant-acinetobacter-baumannii-ventilator-associated-pneumonia-treatment-an-open-label-prospective-study
#4
Demosthenes Makris, Efi Petinaki, Vasssiliki Tsolaki, Efstratios Manoulakas, Konstantinos Mantzarlis, Olimpia Apostolopoulou, Dimitrios Sfyras, Epaminondas Zakynthinos
Background: Retrospective studies have reported good clinical success rates using colistin as monotherapy to treat Acinetobacter baumannii ventilator-associated pneumonia (VAP), comparable to that obtained with colistin combined with other antibiotics. However, inadequate penetration into the pulmonary parenchyma for colistin has been shown in animal models. Aim: The aim of the study was to study prospectively the outcome, measured as clinical response and survival, of intravenously administered colistin versus colistin combined with high-dose ampicillin-sulbactam in Intensive Care Unit (ICU) patients with multiresistant A...
February 2018: Indian Journal of Critical Care Medicine
https://www.readbyqxmd.com/read/29504930/changes-in-antimicrobial-resistance-of-clinical-isolates-of-acinetobacter-baumannii-group-isolated-in-greece-2010-2015
#5
K Dafopoulou, A Tsakris, S Pournaras
In recent years, hospitals in southeastern Europe have faced dramatically high rates of antibiotic-resistant Acinetobacter baumannii. We analysed the evolution of resistance among clinical isolates of A. baumannii group obtained from nine tertiary hospitals throughout Greece over 6 years (2010-2015). Identification and antimicrobial susceptibility testing were performed using Vitek 2 or Microscan walkaway automated systems. Between 2010 and 2015, resistance to ampicillin/sulbactam increased from 46.2 to 88...
March 5, 2018: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/29434938/genetic-characterization-and-in-vitro-activity-of-antimicrobial-combinations-of-multidrug-resistant-acinetobacter-baumannii-from-a-general-hospital-in-china
#6
Fang Chen, Ling Wang, Min Wang, Yixin Xie, Xiaomeng Xia, Xianping Li, Yanhua Liu, Wei Cao, Tingting Zhang, Pengling Li, Min Yang
The present study aimed to develop a rational therapy based on the genetic epidemiology, molecular mechanism evaluation and in vitro antibiotic combinations activity in multidrug-resistant Acinetobacter baumannii (MDRAB). MDRAB was screened by the Kirby-Bauer method. The random amplified polymorphic DNA technique was used to establish genetic fingerprinting, and a series of resistance genes were detected by polymerase chain reaction. Antimicrobial agents including amikacin (AK), cefoperazone/sulbactam (SCF I/II), meropenem (MEM), minocycline (MINO) and ciprofloxacin (CIP) were used to determine the minimum inhibitory concentrations (MICs) and interactions between antibiotics by the broth microdilution method and chequerboard assays...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29394284/the-role-of-the-type-vi-secretion-system-vgrg-gene-in-the-virulence-and-antimicrobial-resistance-of-acinetobacter-baumannii-atcc-19606
#7
Jianfeng Wang, Zhihui Zhou, Fang He, Zhi Ruan, Yan Jiang, Xiaoting Hua, Yunsong Yu
The Type VI Secretion System (T6SS) is an important virulence system that exists in many bacterial pathogens, and has emerged as a potent mediator of pathogenicity in Acinetobacter baumannii. In this study, we inactivated one of the T6SS components vgrG (valine-glycine repeat G) gene in A. baumannii ATCC 19606 and constructed a complementation strain. BEAS-2b human alveolar epithelial cells was adopted to assess bacterial adhesion, and wild female BALB/c mice were used for in vivo experiments to assess the bacterial killing ability to host...
2018: PloS One
https://www.readbyqxmd.com/read/29319497/comparison-of-the-treatment-efficacy-between-tigecycline-plus-high-dose-cefoperazone-sulbactam-and-tigecycline-monotherapy-against-ventilator-associated-pneumonia-caused-by-extensively-drug-resistant-acinetobacter-baumannii
#8
Youfa Qin, Jie Zhang, Lei Wu, Dailong Zhang, Lunjiao Fu, Xiaoyan Xue
OBJECTIVE: The present study examined the effect of high-dose cefoperazone-sulbactam combined with tigecycline against ventilator-associated pneumonia (VAP) caused by extensively drug-resistant Acinetobacter baumannii(XDR-AB). MATERIALS AND METHODS: 42 patients with VAP due to XDR-AB infection were randomized into two groups: the TIG group (received tigecycline injection) and the TIG+CFS group (received tigecycline and cefoperazone-sulbactam (1 : 1) injection)...
March 2018: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29311074/molecular-epidemiology-and-mechanism-of-sulbactam-resistance-in-acinetobacter-baumannii-isolates-with-diverse-genetic-backgrounds-in-china
#9
Yunxing Yang, Ying Fu, Peng Lan, Qingye Xu, Yan Jiang, Yan Chen, Zhi Ruan, Shujuan Ji, Xiaoting Hua, Yunsong Yu
Sulbactam is a plausible option for treating Acinetobacter infections because of its intrinsic antibacterial activity against the members of the Acinetobacter genus, but the mechanisms of sulbactam resistance have not been fully studied in Acinetobacter baumannii In this study, a total of 2,197 clinical A. baumannii isolates were collected from 27 provinces in China. Eighty-eight isolates with various MICs for sulbactam were selected on the basis of their diverse clonality and underwent multilocus sequence typing (MLST), antimicrobial susceptibility testing, and resistance gene screening...
March 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29260856/acinetobacter-baumannii-ompa-is-a-selective-antibiotic-permeant-porin
#10
Ramkumar Iyer, Samir H Moussa, Thomas F Durand-Réville, Ruben Tommasi, Alita Miller
OmpAAb is a conserved, abundantly expressed outer membrane porin in Acinetobacter baumannii whose presumed role in antibiotic permeation has not been clearly demonstrated. In this report, we use a titratable heterologous expression system to express OmpAAb in isolation and demonstrate selective passage of small molecule antibiotics through OmpAAb . ETX2514, a recently discovered broad-spectrum β-lactamase inhibitor, in combination with sulbactam, is currently in clinical testing for the treatment of drug-resistant A...
March 9, 2018: ACS Infectious Diseases
https://www.readbyqxmd.com/read/29244131/reporting-antimicrobial-susceptibilities-and-resistance-phenotypes-in-acinetobacter-spp-a-nationwide-proficiency-study
#11
Felipe Fernández-Cuenca, María Tomás, Francisco-Javier Caballero-Moyano, Germán Bou, Álvaro Pascual
Objectives: To evaluate the proficiency of Spanish microbiology laboratories with respect to the antimicrobial susceptibility testing (AST) of Acinetobacter spp. Methods: Eight Acinetobacter spp. with different resistance mechanisms were sent to 48 Spanish centres which were asked to report: (i) the AST system used; (ii) MICs; (iii) breakpoints used (CLSI versus EUCAST); (iv) clinical category; and (v) resistance mechanisms inferred. Minor, major and very major errors (mE, ME and VME, respectively) were determined...
December 13, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29224317/-a-multicenter-retrospective-study-of-pathogenic-bacteria-distribution-and-drug-resistance-in-febrile-neutropenic-patients-with-hematological-diseases-in-shanghai
#12
J Zhu, J Hu, Y F Mao, F Y Chen, J Y Zhu, J M Shi, D D Yu, S G Hao, R Tao, P Liu, S Y Gu, J Hou, H Y He, A B Liang, Y Ding, L G Liu, Y H Xie, Q Zhu, Y H Yu, Y H Yao, W Chen, H L Xu, X H Han, C Wang
Objective: To investigate the pathogen spectrum distribution and drug resistance of febrile neutropenic patients with hematological diseases in Shanghai. Methods: A retrospective study was conducted on the clinical isolates from the febrile neutropenic patients hospitalized in the departments of hematology in 12 general hospitals in Shanghai from January 2012 to December 2014. The drug susceptibility test was carried out by Kirby-Bauer method. WHONET 5.6 software was used to analyze pathogenic bacteria and drug susceptibility data...
November 14, 2017: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29215335/previous-antibiotic-exposure-and-antimicrobial-resistance-patterns-of-acinetobacter-spp-and-pseudomonas-aeruginosa-isolated-from-patients-with-nosocomial-infections
#13
Zorana M Djordjevic, Marko M Folic, Slobodan M Jankovic
BACKGROUND: The alarming spread of antibiotic-resistant bacteria causing healthcare-associated infections has been extensively reported in recent medical literature. AIMS: To compare trends in antimicrobial consumption and development of resistance among isolates of Acinetobacter spp. and Pseudomonas aeruginosa that cause hospital infections. STUDY DESIGN: Cross-sectional study. METHODS: A study was conducted in a tertiary healthcare institution in central Serbia, during the 7-year period between January 2009 and December 2015...
December 1, 2017: Balkan Medical Journal
https://www.readbyqxmd.com/read/29200878/in-vitro-activity-of-colistin-mono-and-combination-therapy-against-colistin-resistant-acinetobacter-baumannii-mechanism-of-resistance-and-clinical-outcomes-of-patients-infected-with-colistin-resistant-a-baumannii-at-a-thai-university-hospital
#14
Yongyut Lertsrisatit, Wichai Santimaleeworagun, Sudaluck Thunyaharn, Jantima Traipattanakul
Purpose: Colistin is a drug of last resort for treating multidrug-resistant Acinetobacter baumannii infections. Unfortunately, colistin-resistant A. baumannii (CoR-AB) has been reported. Here, we examined the in vitro effect of mono- and combined antimicrobials against CoR-AB strains and their resistance mechanism, and evaluated the clinical outcomes of CoR-AB-infected patients. Patients and methods: Seventeen clinical CoR-AB strains were isolated from patients at Phramongkutklao hospital, 2011-2015...
2017: Infection and Drug Resistance
https://www.readbyqxmd.com/read/29133555/the-frequency-and-mechanism-of-spontaneous-resistance-to-sulbactam-combined-with-the-novel-%C3%AE-lactamase-inhibitor-etx2514-in-clinical-isolates-of-acinetobacter-baumannii
#15
Sarah M McLeod, Adam B Shapiro, Samir H Moussa, Michele Johnstone, Robert E McLaughlin, Boudewijn L M de Jonge, Alita A Miller
The novel diazabicyclooctenone ETX2514 is a potent, broad spectrum serine β-lactamase inhibitor that restores sulbactam activity against resistant Acinetobacter baumannii. The frequency of spontaneous resistance to sulbactam-ETX2514 in clinical isolates was found to be 7.6x10(-10) to <9.0x10(-10) at 4x MIC and mapped to residues near the active site of PBP3. Purified mutant PBP3 proteins demonstrated reduced affinity for sulbactam. In a sulbactam-sensitive isolate, resistance also mapped to stringent response genes associated with resistance to PBP2 inhibitors, suggesting that, in addition to β-lactamase inhibition, ETX2514 may also enhance sulbactam activity in A...
November 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29108947/antibiotic-strategies-and-clinical-outcomes-in-critically-ill-patients-with-pneumonia-caused-by-carbapenem-resistant-acinetobacter-baumannii
#16
C-A Liang, Y-C Lin, P-L Lu, H-C Chen, H-L Chang, C-C Sheu
OBJECTIVES: This study aimed to investigate antibiotic prescribing patterns and effectiveness of different anti-carbapenem-resistant Acinetobacter baumannii (CRAB) strategies for CRAB pneumonia. METHODS: We conducted a multicentre, retrospective study in three hospitals. During 2010-2015, adult ICU patients with CRAB pneumonia treated with at least one antimicrobial agent covering the CRAB isolate in vitro for more than 2 days were included. We used multivariate logistic regression to analyse the associations of anti-CRAB strategies with ICU mortality and other clinical outcomes...
November 3, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29069421/comparative-efficacy-and-safety-of-treatment-options-for-mdr-and-xdr-acinetobacter-baumannii-infections-a-systematic-review-and-network-meta-analysis
#17
Kirati Kengkla, Khachen Kongpakwattana, Surasak Saokaew, Anucha Apisarnthanarak, Nathorn Chaiyakunapruk
Objectives: To comprehensively compare and rank the efficacy and safety of available treatment options for patients with MDR and XDR Acinetobacter baumannii (AB) infection. Methods: We searched PubMed, Embase and the Cochrane register of trials systematically for studies that examined treatment options for patients with MDR- and XDR-AB infections until April 2016. Network meta-analysis (NMA) was performed to estimate the risk ratio (RR) and 95% CI from both direct and indirect evidence...
January 1, 2018: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29061006/-efficacy-of-extended-infusion-of-carbapenem-plus-sulbactam-for-ventilator-associated-pneumonia-caused-by-extensive-drug-resistant-acinetobacter-baumannii
#18
X Wang, Y Hu, C L Que, H Zhang, J J Huang, J Cao, Z Jin, G F Wang, W Zhang
Objective: To evaluate the efficacy of extended-infusion of carbapenem plus sulbactam for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii (XDRAB). Methods: Clinical data of patients with ventilator-associated pneumonia caused by XDRAB who were treated with extended-infusion carbapenem plus sulbactam or tigecycline-based therapy in Peking University First Hospital from January 2015 to December 2016 were collected and reviewed in this retrospective study. Twenty-one patients were treated with extended-infusion carbapenem plus sulbactam, and 20 other patients received tigecycline combined with other antibiotics...
October 17, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28971872/kinetics-of-sulbactam-hydrolysis-by-%C3%AE-lactamases-and-kinetics-of-%C3%AE-lactamase-inhibition-by-sulbactam
#19
Adam B Shapiro
Sulbactam is one of four β-lactamase inhibitors in current clinical use to counteract drug resistance caused by degradation of β-lactam antibiotics by these bacterial enzymes. As a β-lactam itself, sulbactam is susceptible to degradation by β-lactamases. I investigated the Michaelis-Menten kinetics of sulbactam hydrolysis by 14 β-lactamases, representing clinically widespread groups within all four Ambler classes, i.e., CTX-M-15, KPC-2, SHV-5, and TEM-1 for class A; IMP-1, NDM-1, and VIM-1 for class B; Acinetobacter baumannii ADC-7, Pseudomonas aeruginosa AmpC, and Enterobacter cloacae P99 for class C; and OXA-10, OXA-23, OXA-24, and OXA-48 for class D...
December 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28962078/effects-of-specific-egg-yolk-immunoglobulin-on-pan-drug-resistant-acinetobacter-baumannii
#20
Huaying Shi, Jie Zhu, Boyang Zou, Lei Shi, Linying Du, Yayi Long, Huaxin Wang, Hong Xu, Yuhong Zhen, Lidan Sun
With the growing emergence of pan-drug-resistant Acinetobacter baumannii (PDR-Ab) strains in clinical, new strategies for the treatment of PDR-Ab infections are urgently needed. Egg yolk immunoglobulin (IgY) as a convenient and inexpensive antibody has been widely applied to the therapy of infectious diseases. The aim of this study was to produce IgY specific to PDR-Ab and investigate its antibacterial effects in vitro and in vivo. IgYs specific to two PDR-Ab strains were produced by immunizing hens with formaldehyde inactivated PDR-Ab cells and isolated from yolks with a purity of 90% by water dilution, salt precipitations and ultrafiltration...
November 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
keyword
keyword
57609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"